Company Description: Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. By exploiting intrinsic TME-specific metabolites critical to bacterial replication, we have developed a systemically administered but locally targeted and enriched cancer treatment that precisely generates anti-tumor effects. Our lead candidate, ACTM-838, is selectively internalized by myeloid cells directly in the TME, positively activating them, and delivers two highly potent and synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.